Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 10, 2024
- Pharmaceuticals
- R&D
Roche Announces New Four-Year Data of Lunsumio for Relapsed or Refractory Follicular Lymphoma
TOKYO, December 10, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today, regarding four-year data from overseas Phase II study (GO29781) of Lunsumio® (generic name: mosunetuzumab) for relapsed or refractory follicular lymphoma. The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting.
Please refer to the link below for details of the press release:
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
https://www.roche.com/media/releases/med-cor-2024-12-10
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp